{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:25:27Z","timestamp":1787430327682,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca United States","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03618-z","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:45:44Z","timestamp":1780112744000},"page":"3886-3912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining the Roles of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Management of Chronic Kidney Disease in Adults with Type 2 Diabetes With or Without Overweight\/Obesity: An International Delphi Consensus"],"prefix":"10.1007","volume":"43","author":[{"given":"Yehuda","family":"Handelsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Y. Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Fadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fioretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Kanumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Cos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"3618_CR1","unstructured":"Kidney Research UK. Kidney disease: a UK public health emergency. 2023. https:\/\/www.kidneyresearchuk.org\/wp-content\/uploads\/2023\/06\/Economics-of-Kidney-Disease-full-report_accessible.pdf. Accessed May 2025."},{"issue":"4s","key":"3618_CR2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO. 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4s):S117-s314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"key":"3618_CR3","unstructured":"National Institute for Health and Care Excellence. Chronic kidney disease: what are the complications? 2024. https:\/\/cks.nice.org.uk\/topics\/chronic-kidney-disease\/background-information\/complications\/. Accessed May 2025."},{"issue":"10","key":"3618_CR4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30535","volume":"14","author":"R Prasad","year":"2022","unstructured":"Prasad R, Jha RK, Keerti A. Chronic kidney disease: Its relationship with obesity. Cureus. 2022;14(10):e30535. https:\/\/doi.org\/10.7759\/cureus.30535.","journal-title":"Cureus"},{"issue":"4","key":"3618_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1681\/ASN.2020101472","volume":"32","author":"AN Friedman","year":"2021","unstructured":"Friedman AN, Kaplan LM, le Roux CW, Schauer PR. Management of obesity in adults with CKD. J Am Soc Nephrol. 2021;32(4):777\u201390. https:\/\/doi.org\/10.1681\/ASN.2020101472.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3618_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13098-023-01202-x","volume":"15","author":"ET Fenta","year":"2023","unstructured":"Fenta ET, Eshetu HB, Kebede N, Bogale EK, Zewdie A, Kassie TD, et al. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15(1):245. https:\/\/doi.org\/10.1186\/s13098-023-01202-x.","journal-title":"Diabetol Metab Syndr"},{"issue":"1 Suppl 1","key":"3618_CR7","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","volume":"48","author":"American Diabetes Association Professional Practice C","year":"2025","unstructured":"American Diabetes Association Professional Practice C. 11. Chronic kidney disease and risk management: standards of care in diabetes. Diabetes Care. 2025;48(1 Suppl 1):S239\u201351. https:\/\/doi.org\/10.2337\/dc25-S011.","journal-title":"Diabetes Care"},{"issue":"10","key":"3618_CR8","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849\u201356. https:\/\/doi.org\/10.1038\/s41591-024-03133-0.","journal-title":"Nat Med"},{"issue":"2","key":"3618_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"24","key":"3618_CR10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"3618_CR11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"3618_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"3","key":"3618_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.4093\/dmj.2025.0220","volume":"49","author":"JH Bae","year":"2025","unstructured":"Bae JH. SGLT2 inhibitors and GLP-1 receptor agonists in diabetic kidney disease: evolving evidence and clinical application. Diabetes Metab J. 2025;49(3):386\u2013402. https:\/\/doi.org\/10.4093\/dmj.2025.0220.","journal-title":"Diabetes Metab J"},{"issue":"8","key":"3618_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100851","volume":"6","author":"M Madero","year":"2024","unstructured":"Madero M, Chertow GM, Mark PB. SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health. Kidney Med. 2024;6(8):100851. https:\/\/doi.org\/10.1016\/j.xkme.2024.100851.","journal-title":"Kidney Med"},{"issue":"17","key":"3618_CR15","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1056\/NEJMc2513088","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R, Rossing P, Mann JFE. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025;393(17):1755. https:\/\/doi.org\/10.1056\/NEJMc2513088.","journal-title":"N Engl J Med"},{"key":"3618_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-026-03559-7","author":"Y Handelsman","year":"2026","unstructured":"Handelsman Y, Cheng A, Fadini GP, Kushner P, Bonnet F, Fioretto P, et al. Evidence-based positioning of sodium-glucose co-transporter protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in the management of chronic kidney disease with type 2 diabetes and overweight or obesity: a systematic literature review. Adv Ther. 2026. https:\/\/doi.org\/10.1007\/s12325-026-03559-7.","journal-title":"Adv Ther"},{"issue":"8","key":"3618_CR17","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1111\/dom.15652","volume":"26","author":"S Tsukamoto","year":"2024","unstructured":"Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, et al. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2024;26(8):3248\u201360.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3618_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004326","volume":"21","author":"WT Gattrell","year":"2024","unstructured":"Gattrell WT, Logullo P, van Zuuren EJ, Price A, Hughes EL, Blazey P, et al. ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med. 2024;21(1):e1004326. https:\/\/doi.org\/10.1371\/journal.pmed.1004326.","journal-title":"PLoS Med"},{"issue":"8","key":"3618_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1177\/0269216317690685","volume":"31","author":"S Junger","year":"2017","unstructured":"Junger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on conducting and reporting DElphi studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med. 2017;31(8):684\u2013706. https:\/\/doi.org\/10.1177\/0269216317690685.","journal-title":"Palliat Med"},{"issue":"8","key":"3618_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12(8):545\u201357. https:\/\/doi.org\/10.1016\/S2213-8587(24)00155-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"3618_CR21","doi-asserted-by":"publisher","first-page":"771","DOI":"10.34067\/KID.0000000000000425","volume":"5","author":"A Upadhyay","year":"2024","unstructured":"Upadhyay A. SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback. Kidney360. 2024;5(5):771\u201382. https:\/\/doi.org\/10.34067\/KID.0000000000000425.","journal-title":"Kidney360"},{"issue":"1","key":"3618_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01197-z","volume":"20","author":"T Yamada","year":"2021","unstructured":"Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021;20(1):14. https:\/\/doi.org\/10.1186\/s12933-020-01197-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"3618_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1089\/dia.2015.0007","volume":"17","author":"A Misra","year":"2015","unstructured":"Misra A. Ethnic-specific criteria for classification of body mass index: a perspective for Asian Indians and American Diabetes Association position statement. Diabetes Technol Ther. 2015;17(9):667\u201371. https:\/\/doi.org\/10.1089\/dia.2015.0007.","journal-title":"Diabetes Technol Ther"},{"key":"3618_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60101668","author":"L Ozbek","year":"2024","unstructured":"Ozbek L, Abdel-Rahman SM, Unlu S, Guldan M, Copur S, Burlacu A, et al. Exploring adiposity and chronic kidney disease: clinical implications, management strategies, prognostic considerations. Medicina. 2024;60(10). https:\/\/doi.org\/10.3390\/medicina60101668.","journal-title":"Medicina"},{"issue":"3","key":"3618_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061807","volume":"13","author":"H Ma","year":"2023","unstructured":"Ma H, Lin YH, Dai LZ, Lin CS, Huang Y, Liu SY. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2023;13(3):e061807. https:\/\/doi.org\/10.1136\/bmjopen-2022-061807.","journal-title":"BMJ Open"},{"issue":"4","key":"3618_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"12","key":"3618_CR27","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SO, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial. Diabetes Care. 2019;42(12):2272\u201381. https:\/\/doi.org\/10.2337\/dc19-0883.","journal-title":"Diabetes Care"},{"issue":"10193","key":"3618_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"19","key":"3618_CR29","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"key":"3618_CR30","first-page":"223","volume":"26","author":"P Brown","year":"2024","unstructured":"Brown P. Diabetes distilled: ABCD\u2013UKKA concise recommendations for management of CKD in type 2 diabetes. Diabetes Prim Care. 2024;26:223\u20136.","journal-title":"Diabetes Prim Care"},{"key":"3618_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003991","author":"M Franchi","year":"2024","unstructured":"Franchi M, Pellegrini G, Avogaro A, Buzzetti G, Candido R, Cavaliere A, et al. Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2024;12(3). https:\/\/doi.org\/10.1136\/bmjdrc-2023-003991.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"3618_CR32","doi-asserted-by":"crossref","unstructured":"Niu S, Bhatt P, Puyat V, Cohen J, Erickson K, editors. 1066-P: Cost-effectiveness of SGLT2i plus GLP-1RAs vs. SGLT2i in patients with chronic kidney disease. American Diabetes Assocation, 85th Scientific Sessions; 2025; Chicago, Illinois.","DOI":"10.2337\/db25-1066-P"},{"key":"3618_CR33","doi-asserted-by":"crossref","unstructured":"Rossing P, Lindhardt M, Tikkanen CK, Menon J, Cattin J, Hunt B, et al., editors. 782-P: Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: a long-term cost-effectiveness analysis based on FLOW. 85th Scientific Sessions of the American Diabetes Association; 2025; Chicago.","DOI":"10.2337\/db25-782-P"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03618-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03618-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03618-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:01:19Z","timestamp":1787428879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03618-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3618"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03618-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article was revised due to update in Funding Information.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have declared any relevant competing interests. Yehuda Handelsman: Received research grants, consultant and speaker honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Eli Lilly, Ionis, Merck, Novo Nordisk, Regeneron, Sanofi, Verdiva Bio; Alice Cheng: Received consulting and speaking honoraria from Abbott, Astellas, Aspen, AstraZeneca, Amgen, Bausch, Bayer, Biomea Fusion, Boehringer Ingelheim, Dexcom, Eisai, Eli Lilly, GSK, HLS Therapeutics, Insulet, Medtronic, Merck, MSD, Novo Nordisk, Pfizer, Sandoz, Sanofi, and Vertex; Gian Paolo Fadini: Received grants, honoraria or lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Guidotti, Mundipharma, Novartis, Novo Nordisk, Servier, and Sanofi; Pam Kushner: Received honoraria for consulting or advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Verdiva Bio; Fabrice Bonnett: No competing interests; Paola Fioretto: Received fees as consultant and speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Novo Nordisk; Takashi Kadowaki: Received research grants from Nippon Boehringer Ingelheim Co., Ltd. and Sumitomo Pharma Co., Ltd.; receiving consulting fees from Taisho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K. and Novo Nordisk Pharma Ltd.; receiving honoraria for lectures from Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Pharma Co., Ltd., Teijin Pharma Ltd., MSD Corporation, Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical Co., Ltd. and Novo Nordisk Pharma Ltd; Naresh Kanumilli: No competing interests; Xavier Cos: No competing interests; Thomas Frese: Received payments from Astra Zeneca and Boehringer Ingelheim; Linong Ji: No competing interests; Peter Rossing: Received consultancy and\/or speaker fees (to his institution) from Abbott, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Novo Nordisk and Roche; research grants from AstraZeneca, Bayer and Novo Nordisk; study drugs from AstraZeneca, Bayer Lexicon and Novo Nordisk.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No patients were involved in the study, which was not submitted for approval by an ethics committee or institutional review board. Participants gave informed consent to participate in the study before taking part and were made aware of the study objectives and the aim for publication of a manuscript. Participants remained independent throughout the Delphi panel; no honoraria were provided for their time or participation in the surveys, and their responses were anonymised from each other and the funder throughout the surveys.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}